Скачать или смотреть Cells, Tox and Rock ’n’ Roll Cell Validation and Drug Induced Liver Injury Using a Human Liver Mic

Presented By:
Christiana Skarlatopoulou

Speaker Biography:
Christiana Skarlatopoulou is a Scientist in the Contract Research Services Team at CN Bio. Before joining CN Bio, she was a research Technician for Twin Research and Genetic Epidemiology at King’s College London (KCL) and then went on to graduate from the Biomedical and Molecular Research MRes programme at KCL. During her MRes, her main research projects focussed on tissue engineering and hepatic organoids. Since joining CN Bio, Christiana has leveraged her extensive knowledge on cell culture and 3D liver models to deliver contract research projects to clients. Service projects utilize CN Bio’s CN Bio’s PhysioMimix™ OOC range of microphysiological systems to culture predictive human models of the liver for Drug-Induced Liver Injury (DILI) studies, or to recapitulate liver diseases, notably Non-Alcoholic Steatohepatitis (NASH) for target identification, validation, and drug efficacy testing.

Webinar:
Cells, Tox and Rock 'n' Roll - Cell Validation and Drug-Induced Liver Injury Using a Human Liver Microphysiological System

Webinar Abstract:
Ninety percent of therapeutic agents reaching clinical trial fail to reach entry to market, with safety concerns being a major cause for failures in phase I and II clinical trials. Drug-induced liver injury (DILI) is one of the most common reasons for acute liver failure in both Europe and US and is also one of the leading causes for cessation of drug development. This is predominantly due to traditional preclinical models failing to adequately predict human responses to a drug . Moreover, Drugs with human-specific modes of action, such as ASOs or siRNA, are less well served by in vivo animal models due to their human-specific modes of action.

Incorporating more predictive, human relevant models into drug development workflows is key to reducing drug attrition. Microphysiological systems (MPS), also known as organ-on-a-chip (OOC), bridge the gap between preclinical testing and the clinic. MPS enable us to better recapitulate human physiology via the use of human cells and circulating flow to simulate the blood stream. Yet, without the supply of good quality cells, validated for use in 3D assay formats, the advantages of MPS over current preclinical models can't be fully realized. This presentation will demonstrate the clinical predictability of a Liver MPS using OOC-validated liver cells and a validation set of mildly to severely hepatotoxic compounds, plus two new drug modalities (ASOs).

Earn PACE Credits:
1. Make sure you're a registered member of LabRoots (https://www.labroots.com/webinar/cell...)
2. Watch the webinar on the LabRoots Website (https://www.labroots.com/webinar/cell...)
3. Click Here to get your PACE credits (Expiration date – FEB 22, 2025): https://www.labroots.com/credit/pace-...

LabRoots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc